US protection ending in 2030: Heart and blood vessels
As of the edition of 20 October 2026, 23 drugs have US protection that ends in 2030 in heart and blood vessels; 19 of them have at least one company on route B because of it.
Sources: FDA Orange Book and Purple Book, other approval registers.
23 drugs
| Drug | US protection | Status | Holder | Target | Route B rows |
|---|---|---|---|---|---|
| Aflibercept | Ends 2030 (orphan exclusivity) | Marketed | Regeneron | PGF, VEGFA | 4 |
| Andexanet alfa | Ends 2030 (computed from the first US licence) | Marketed | AstraZeneca | TFPI | 0 |
| Axitinib | Ends 2030 (patent) | Marketed | Pfizer | FLT1, FLT4, KDR | 0 |
| Cemiplimab | Ends 2030 (computed from the first US licence) | Marketed | Regeneron | PDCD1 | 2 |
| Cenegermin | Ends 2030 (computed from the first US licence) | Marketed | Dompé Farmaceutici | NTRK1, NTRK2, NTRK3 | 3 |
| Dabrafenib | Ends 2030 (patent) | Marketed | Novartis | BRAF | 1 |
| Doxecitine | Ends 2030 (exclusivity) | Marketed | UCB | 0 | |
| Emapalumab | Ends 2030 (computed from the first US licence) | Marketed | Swedish Orphan Biovitrum | IFNG | 1 |
| Encorafenib | Ends 2030 (exclusivity) | Marketed | Pfizer | BRAF | 3 |
| Erenumab | Ends 2030 (computed from the first US licence) | Marketed | Amgen | CALCRL | 1 |
| Etripamil | Ends 2030 (exclusivity) | Marketed | Milestone Pharmaceuticals | CACNA1C | 1 |
| Lanadelumab | Ends 2030 (computed from the first US licence) | Marketed | Takeda | KLKB1 | 1 |
| Neratinib | Ends 2030 (patent) | Marketed | Puma Biotechnology | EGFR | 2 |
| Pacritinib | Ends 2030 (patent) | Marketed | Swedish Orphan Biovitrum | FLT3, JAK2 | 2 |
| Pimavanserin | Ends 2030 (patent) | Marketed | Acadia Pharmaceuticals | HTR2A | 1 |
| Ravulizumab | Ends 2030 (computed from the first US licence) | Marketed | AstraZeneca | C5 | 0 |
| Selexipag | Ends 2030 (patent) | Marketed | Johnson & Johnson | PTGIR | 1 |
| Sildenafil | Ends 2030 (exclusivity) | Marketed | Viatris | PDE5A | 3 |
| Sotagliflozin | Ends 2030 (patent) | Marketed | Lexicon Pharmaceuticals | SLC5A2 | 2 |
| Tagraxofusp | Ends 2030 (computed from the first US licence) | Marketed | Stemline Therapeutics | EEF2, IL3RA | 4 |
| Tildrakizumab | Ends 2030 (computed from the first US licence) | Marketed | SUN Pharmaceutical Industries | IL23A | 1 |
| Trametinib | Ends 2030 (patent) | Marketed | Novartis | MAP2K1, MAP2K2 | 2 |
| Vemurafenib | Ends 2030 (patent) | Marketed | Roche | BRAF | 1 |
Listed by name. A route B row is one company at one target; for a drug with one target that is the number of companies. US protection is the US only, and it is not the date generics or biosimilars can enter.
Which companies are on route B in 2030 in heart and blood vessels
In the product19 of these 23 drugs have at least one company on route B. Which companies, and their scores, are in the product.
Get this list with the companies, scores and sources as a fileRequest access. Nothing is shown until you do.